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Abstract 
Nuclear magnetic resonance (NMR) spectroscopy has a unique capability to probe the 
primary and higher order molecular structure and the structural dynamics of biomolecules at 
an atomic resolution, and this capability has been greatly fortified over the last five decades 
by an astonishing NMR instrumental and methodological development. Because of these 
factors, NMR has become a primary tool for the structure investigation of biomolecules, 
spawning a whole scientific subfield dedicated to the subject. This role of NMR is by now 
well established and broadly appreciated, especially in the context of academic research 
dealing with proteins that are purified and isotope-labeled in order to facilitate the necessary 
sophisticated multidimensional NMR measurements. However, the more recent industrial 
development, manufacturing, and quality control of biopharmaceuticals provide a different 
framework for NMR. For example, protein drug substances are not isotope-labeled and are 
present in a medium of excipients, which make structural NMR measurements much more 
difficult. On the other hand, biotechnology involves many other analytical requirements that 
can be efficiently addressed by NMR. In this respect the scope and limitations of NMR are 
less well understood. Having the non-expert reader in mind, herein we wish to highlight the 
ways in which modern NMR can effectively support biotechnological developments. Our 
focus will be on biosimilar proteins, pointing out certain cases where its use is probably 
essential. Based partly on literature data, and partly on our own hands-on experience, this 
paper is intended to be a guide for choosing the proper NMR approach for analytical 
questions concerning the structural comparability of therapeutic proteins, monitoring 
technology-related impurities, protein quantification, analysis of spent media, identification 
of extractable and leachable components, etc. Also, we focus on critical considerations, 
particularly those coming from drug authority guidelines, which limit the use of the well-
established NMR tools in everyday practice.  
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1. Introduction 
In the last two decades the global biopharmaceuticals market has increased 
dramatically. Accordingly, several new companies specializing entirely in the research, 
analytics, or production of biopharmaceuticals have appeared, and most of the big traditional 
pharmaceutical companies have opted for introducing biopharmaceuticals at a growing ratio 
in their product portfolio.  
For small-molecule drug substances and drug products the analytical techniques that 
are obligatory for their detailed structural characterization and quality control are well 
consolidated and are generally well known (at least at a conceptual level) by the non-
analytical experts. However, in the field of industrial biotherapeutics the analogous demands 
on bioanalytics are not only rapidly changing, requiring a constant adaptation to the 
regulatory requirements [1], but form a certain “gray zone” within which companies may 
interpret what kinds of analytical methodologies, what level of instrumentation, and what 
level of experimental detail they want to, or are willing to employ. Making the right 
corporate-level decisions in that regard is certainly not easy. One important aspect of this 
problem is that the strategies for the structure investigation of biological macromolecules 
differ from those used for small molecules. This is not only because of the difference in 
molecule size and structural complexity, but also because the concept of a “structure” is less 
well-defined in biomolecules. For example, in large proteins the higher-order structure is a 
dynamical feature of the molecule that can change subtly depending on the circumstances. 
Also, because the production and formulation of biologics is very different from traditional 
drugs, there are small average differences between batches, and specific differences between 
individual molecules, in terms of the post-translational modifications of a protein. This basic 
difference between small and large molecules is also reflected in the terms “generic” and 
“biosimilar”, as used for the respective follow-on drug substances. While for generic small 
molecules the original and the follow-on drug substance must be analytically demonstrated to 
have exactly the same structure, for biosimilars the follow-on substance must be shown to be 
sufficiently “similar” to the original, and the latter task calls for new analytical approaches. 
Furthermore, the function of bioanalytics covers not only the structural characterization of 
macromolecules, but quite often the application of a state-of-the-art analytical background is 
required to support the midstream and downstream biotechnological processes of drug 
production as well. Within this new, dynamic and diverse landscape of biopharmaceuticals 
the role of nuclear magnetic resonance (NMR) spectroscopy is also diverse, differs in many 
respects from its common applications, and is not well understood in general.  
With the above considerations in mind, in this review we wish to highlight the unique 
role that NMR spectroscopy can play regarding the quality control and regulatory aspects of 
biotechnological products, with special focus placed on the emerging analytical questions that 
can be answered by NMR during the development of protein biosimilars. In addition to 
reviewing the most relevant recent literature, our discussion is guided by our own hands-on 
experience gained in bioanalytics over the last decade in the region’s prominent 
pharmaceutical company, Gedeon Richter Plc.  
To clarify the scope of this review, we first need to point out the circumstances that 
can limit the range of applicable NMR tools in the biopharmaceutical industry. In the 
discovery phase of protein drug substances, NMR spectroscopy is one of the major tools for 
the characterization of solution-phase macromolecular structure and dynamics. This is 
because at this stage isotope-labeled (i.e., enriched in the NMR-active nuclei 13C and/or 15N), 
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proteins are used, which is a prerequisite for the large number of sophisticated 
multidimensional NMR techniques that may be employed for probing a structure at atomic 
resolution [2]. Under these circumstances the researchers are mostly free to choose the 
scheme of isotopic enrichment, the solution conditions that are the most advantageous for the 
studied molecular system, and thus the optimal NMR method for addressing the pertinent 
structural question. In contrast, this methodological repertoire becomes much more limited in 
the industrial development phase. At this stage biologics must to be analyzed with natural 
isotopic abundance and very often in the presence of other components that may hamper the 
NMR investigations. For biosimilars the initial characterization of the drug substance and the 
drug product, followed by the comparability studies involving their originator counterpart, 
must be performed without any modification of the solution. Other types of analytical tasks 
that NMR can provide at certain steps of the biotechnological procedures (e.g. spent broth 
analysis, or the structural characterization of unknown contaminants, or protein 
quantification) are also preferably carried out with minimal modification of the sample. Due 
to these special conditions, the biggest challenge for the NMR spectroscopist in the 
biopharmaceutical industry is, on the one hand, to recognize the analytical question that can 
be answered by NMR, and on the other hand to creatively chose among the applicable 
techniques from the vast set of the NMR toolbox.  
There are some concerns that may be raised against using NMR for macromolecular 
characterization in an industrial environment, such as its low sensitivity compared to other 
techniques, most typically mass spectrometry (MS), whereby much more substance must be 
used for the measurements which can also take excessively long times, and the requirement 
for using costly state-of-the-art instrumentation. Herein we wish to demonstrate that although 
these drawbacks of NMR are true, the information that NMR can provide is in many cases 
inaccessible by any other method. Moreover, the constant improvements in NMR technology 
keep alleviating – at least in partly – these limiting attributes. Although NMR is not the 
dominant analytical technique in the biopharmaceutical industry, its use as a complementary 
method is either useful, or sometimes inevitable. The growing number of scientific papers in 
this field also indicates that NMR is rapidly gaining an increasingly solid foothold in the 
arena of biopharmaceuticals. 
 
2. Structure investigation of therapeutic proteins 
2.1 NMR in the context of the regulatory requirements for biosimilars 
 
As already noted in the Introduction, analogously to the generic drug substances, 
biologics also have their follow-on versions, usually referred to as biosimilars. Due to the 
high structural complexity, and in some respects inherent structural diversity of therapeutic 
proteins, the exact identity of the follow-on and the originator’s drug substance (which is 
itself a structurally diverse entity with some batch-to-batch variations) cannot be achieved in 
practice. Moreover, apart from the fact that the primary structures of the relevant proteins 
must be identical, with respect to other structural features the criteria for “similarity” are 
more difficult to define, and the pertinent regulatory requirements are changing as the field 
evolves. According to the FDA, biosimilars are “highly similar to the reference product they 
were compared with, but have no clinically meaningful differences in terms of safety, purity 
and potency from the reference product”[1]. The criteria for what differences between the 
originator and the generic products are, or are not acceptable, cannot be uniformly defined, 
because not all of the molecular features are equally relevant regarding the biological activity 
of a biopharmaceutical drug substance. Thus, the critical “similarity-parameters” must be 
established for each individual case. Although this task is challenging and leaves a certain 
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space for judgment for the developers of a biosimilar molecule, if done wisely, meticulously 
and scientifically convincingly, it can forcefully demonstrate the quality of the biosimilar 
product.  
A question often raised in connection with the application of NMR in comparability 
studies is whether the employed method should be validated. NMR methods are considered 
as state-of-the-art structure-elucidation tools which, according to recent recommendations 
[3], should not necessarily be validated, but must be based on sound science. If an NMR 
method has already been described in a monograph, one only needs to verify its suitability for 
the employed conditions; validation is required only when an NMR method is used as an 
alternative to the official procedure. [3,4] 
One of the most difficult tasks of biosimilar comparability studies is the monitoring of 
the protein higher order structure (HOS) during drug development so as to prove that any 
batch-to-batch variability in the product is within acceptable limits (just as with the 
orginator’s molecule). The most commonly applied analytical methods in comparability 
studies, such as liquid chromatography, different types of electrophoresis, bioassays, MS and 
peptide mapping give detailed information mainly about the covalent structure of the protein 
(i.e., the amino acid sequence, posttranslational modifications such as disulfide bridges, 
glycosylation, etc.), together with other related structural features such as the intact molecular 
mass, charge, and aggregation, but tell us nothing or very little about the HOS.  Further 
complementary methods like proton-deuterium exchange mass spectrometry (HDX-MS), 
Fourier transform infrared spectroscopy (FT-IR), circular dichroism (CD), and differential 
scanning calorimetry (DSC) are capable of providing some insight into the higher order 
protein structure as well, but this information is indirect or sensitive to global differences in 
the secondary and tertiary structure (CD, FT-IR, DSC), therefore structural differences cannot 
be localized. Only HDX-MS gives sufficiently detailed information about the local changes 
in protein conformation and conformational dynamics [5–7], but at the expense of labor-
intensive sample preparation and with some difficulties in terms of reproducibility. Thus, 
when it comes to HOS, NMR is in principle a unique player on the scene, with its special 
capability of providing highly exact and detailed information about the three-dimensional 
(3D) structure at atomic resolution.  
However, the detailed NMR characterization of the 3D structure of formulated 
therapeutic molecules is quite challenging. This is because without isotopic labeling, and in 
the presence of the buffer and stabilizers used for the formulation of a protein drug substance, 
only significantly fewer NMR experiments can be used, making resonance assignment and de 
novo structure determination practically unattainable. Fortunately, for the purposes of the 
comparability and quality-control studies in question such detailed NMR characterization of 
the solution structure is not imperative, and quite a lot of useful information can be acquired 
from experiments that use the most common element in organic compounds, which also 
happens to be the most sensitively detectable nucleus in NMR, namely 1H. Unlike in CD and 
IR spectroscopy, in the 1H NMR spectrum of a protein the signals originate from the 
individual atoms, all reflecting their own local chemical environment by their chemical shift. 
The chemical shift is a highly sensitive function of the constitution, configuration and 
conformation of the molecule, and the 1H chemical shifts differ slightly, but usually 
measurably (depending on the spectral resolution) for each individual 1H nucleus within a 
protein. Thus, envisioning an idealistic situation where each 1H NMR signal of a protein is 
fully resolved, the spectrum is essentially an atomic-level spectral fingerprint which uniquely 
encodes the constitution together with the HOS of the protein. In reality this of course is not 
the case, and signal overlaps often “smear” certain regions of the “fingerprint” (Figure 1.) 
Nevertheless, even in such cases the 1H NMR spectrum typically provides enough atomic-
resolution detail that will allow one to make a fast and very reliable comparison of the 
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constitutional and HOS-level likeness of two “similar” protein drug substances. Should a 
one-dimensional (1D) 1H NMR spectrum prove not to be sufficiently detailed for that 
purpose, two-dimensional (2D) NMR spectra may be recorded in which the resonances are 
represented as cross-peaks that carry information about various through-bond or through-
space atomic connections within a molecule. These 2D spectra are generated via a 
sophisticated sequence of radio-frequency pulses, the theory and application of which is a 
subfield of NMR in its own right, and is often referred to as “spin gymnastics”. In the present 
context, the most important such 2D experiments are as follows. a) The 1H-1H NOESY 
(nuclear Overhauser effect spectroscopy) experiment shows the 1H-1H pairs that are in close 
spatial proximity (only a few Ångströms apart); b) the 1H-13C and 1H-15N HSQC 
(heteronuclear single quantum correlation spectroscopy) or HMQC (heteronuclear multiple 
quantum correlation spectroscopy) experiments reveal the one-bond H-C and H-N moieties in 
the molecule. Each experiment gives a specific pattern of cross-peaks (a 2D fingerprint) 
which is, again, unique for the given protein in terms of its primary and higher order 
structure. These 2D fingerprints have a much higher resolution (particularly the heteronuclear 
versions) than the 1D 1H NMR fingerprint. It should be noted that 13C and 15N can be found 
in a relative natural abundance of 1.3 and 0.4 %, respectively, which still allows the recording 
of heteronuclear 2D experiments, albeit at a sensitivity which is approximately two orders of 
magnitude less than for uniformly isotope-labeled proteins. 
 
In the scientific literature, publications describing the above concepts started to appear 
only relatively recently. For the biosimilar version of the protein drug substances filgrastim 
and rituximab, 1D 1H NMR spectra were compared visually with those of the respective 
original products as a part of a comparability exercise. [8,9]  Freedberg [10] suggested the 
use of 1H-1H NOESY as an additional method for fingerprinting. The NOESY experiment 
was applied to prove the structural identity of biosimilar proteins to the reference product of 
filgrastim [11] and rituximab [12]. 
As mentioned above, the 1H NMR structural fingerprinting of formulated therapeutic 
proteins can be difficult because of the extra signals due to the excipients. Such additives are 
usually small organic molecules and their molar concentration is significantly higher than that 
of the protein drug substance, thus producing intensive signals which often overlap with 
important regions of the protein signals in the 1D 1H or homonuclear 2D spectra, limiting the 
available fingerprint information. A possible way to work around this difficulty is to do a 
complete buffer exchange for both the original and the “similar” protein before NMR 
measurement. This act may induce some minor alterations in the 3D structure of the drug 
substance, but since this change is expected to affect the reference and the follow-on proteins 
identically, technically the obtained NMR fingerprints will be relevant as a basis of the 
comparison. Care must be taken however with this approach, because the fact that a modified 
version of the reference product is used for the comparison may be questionable from the 
point of view of the authorities. 
Another solution for the suppression of additive signals was suggested by Poppe and 
coworkers [13], who exploited the difference in the diffusion properties of the small excipient 
molecules and the large protein. By implementing the principles of the so-called diffusion 
ordered spectroscopy (DOSY) NMR experiment which can separate signals as a function of 
their translational diffusion coefficient, they could successfully eliminate the intensive 
excipient signals from 1D 1H NMR spectra. Their method was employed for different 
monoclonal antibody (mAb) samples, which are the largest therapeutic proteins, although it 
works well for smaller proteins. Feng and coworkers [14] used so-called first-increment 
NOESY-based experiments in NMR comparability studies involving the protein drug 
substances daptomycin and trastuzumab. Franks and coworkers [15] proposed an interesting 
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1D 1H fingerprint-enhancing method that can be used to remove the small-molecule excipient 
signals, together with signals that are due to the highly flexible regions of the protein, from 
the signals associated with the more rigid parts of the protein. The method exploits the fact 
that small molecules, as well as the highly flexible parts of large molecules, have very 
different relaxation characteristics from the more rigid parts of large molecules. One 
important aspect of this difference is that in the latter case a phenomenon known as spin 
diffusion is far more efficient than in the former cases. Due to this efficient spin diffusion, the 
saturation (i.e., the quenching of a signal by using a suitably selective and long irradiation) of 
any part of the spectrum that is associated with the rigid region of the protein will saturate all 
other signals as well that originate from that region (note that small molecules and the 
flexible protein parts do not show this effect). Thus, if one subtracts a spectrum obtained by 
using such saturation from a control spectrum recorded without saturation, one obtains a 
spectrum that will give a fingerprint of the more rigid parts of the protein, essentially 
eliminating the excipient signals. By another approach which was suggested by Skidmore et 
al. [16], the  protein signals can be filtered out from the spectra using the so-called Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence, which works on the basis of the large 
difference between how fast a protein and a small molecule rotates in solution. This method 
[16] proved to be more useful for the characterization of small molecules in the presence of 
macromolecules and will be further discussed in Chapter 2.1. 
With increasing molecular weight, the 1H NMR spectrum not only becomes more 
crowded, but the resonances also become broader, and beyond a certain protein size the two 
effects start to limit the use of the method as a diagnostic molecular fingerprint. The higher 
the magnetic field, the larger the so-called Larmor frequency with which NMR-active spins 
precess within the magnetic field. A magnet’s strength is commonly defined as the 
approximate 1H Larmor frequencies associated with that given magnet. With increasing 
magnetic field strengths, the resonance frequencies will spread over a larger frequency span, 
yielding increased spectral resolution. At the currently available high-end magnetic fields 
(700MHz - 1000MHz), the practical protein size limit for 1H based NMR experiments is 
approximately 200kDa. 
 
As mentioned above, in order to resolve heavy signal overlapping, 2D heteronuclear 
correlation methods can be used. A 2D 1H-15N HSQC spectrum will be less crowded, because 
it only shows cross-peaks that represent the H-N units in the molecule, with each cross-peak 
belonging to one amino acid residue (Figures 3, 4). Additionally, because the excipient 
usually does not contain NH or NH2 groups, it does not give cross-peaks in the 
1H-15N HSQC 
spectrum.  Since the amino acid residues observed in the 1H-15N HSQC experiment are 
situated in the protein backbone, and are usually involved in hydrogen bonding, their 
chemical shifts are extremely sensitive to any change in the H-bond pattern and backbone 
conformation. Thus the 1H-15N HSQC seems to be highly suitable choice for structural 
fingerprinting. However, a major drawback of this method is that the recording of a 1H-15N 
HSQC spectrum with adequate signal-to-noise ratio can be excessively time consuming 
because of the fact that the natural abundance of the NMR-active 15N nucleus is only 0.4%. 
For example, using a non-isotope-enriched protein sample of 0.5-1mM concentration, on a 
high-field NMR instrument (700MHz and above) equipped with cryogenically cooled signal-
reception coils (so as to enhance the signal-to-noise ratio) a 1H-15N-HSQC spectrum (Figure 
3.) can be recorded in approximately 40 to 90 hours,  depending on the protein size and the 
applied 2D pulse sequence. Methodological improvements concerning the fine details of 
pulse sequences were developed in the last decade in order to significantly reduce the time of 
data acquisition. As a result of these developments, the so called SOFAST (alternatively 
referred to as BEST) versions of HSQC and HMQC experiments became available. An 
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alternative acquisition method known as non-uniform sampling (NUS) resulted in a further 
reduction in the overall experimental time. In the case of 2D methods, if the acquisition 
parameters of NUS and its related data processing parameters are set properly, the experiment 
time can be reduced by half without disadvantageous artifacts on the spectra [17,18]. These 
rapid acquisition methods proved to be extremely useful for recording NMR fingerprints of 
therapeutic proteins [12,17,19,20]. 
The 1H-15N HSQC method was successfully applied to assess the identity of the 
bioactive conformation of recombinant insulin [21] , interferon alpha [22], and the most 
extensively investigated therapeutic protein, the human granulocyte macrophage-colony 
stimulation factor (GCSF) [23]. 
In practice, well-resolved 1H-15N HSQC spectra may be recorded at natural isotopic 
abundance from proteins weighing up to about 50kDa. Most of the therapeutic proteins are 
mAbs (Figure 2) whose average molecular size is above this limit (Table 1). Arbogast and 
coworkers [17] described a protocol in which enzymes were used to cleave the monoclonal 
antibodies (up to 150kDa) into measurable parts. They proved that the cleavage did not 
modify significantly the HOS of the truncated parts as compared to the intact molecule, and 
the resulting pieces of proteins are already small enough for HSQC measurement. 
  
The aforementioned examples show that NMR fingerprinting can be an invaluable 
tool for assessing the structural similarity of biopharmaceuticals. If the NMR fingerprints are 
sufficiently detailed, due to their super-sensitivity to minor structural changes, an excellent 
match can be regarded as a strong experimental support for a very high degree of structural 
similarity between the compared proteins. This sensitivity however can also have drawbacks: 
slight differences in the solution conditions may cause minor, but from a practical viewpoint 
irrelevant differences in the 3D structure (such as those shown in Fig. 4 – see below), easily 
leading to observable spectral mismatches. Moreover, some spectral differences may stem 
purely from inevitable differences in the instrumental measurement conditions. Even when 
using the same NMR spectrometer in a comparability study, the NMR spectra will be 
recorded at different times, entailing slight differences in magnet homogeneity, pulse power, 
etc. The ensuing spectral differences may be indistinguishable from those originating from 
structural dissimilarities that are unrelated to the solution conditions. Which spectral 
difference is meaningful or irrelevant regarding the assessment of structural similarity is 
therefore a question that requires careful expert judgment.  
Aubin and coworkers [23] addressed the following question. When assessing the 
formulation-dependent variations observed in the location of the amide-region cross-peaks in 
the 1H-15N HSQC spectra, to what extent can these changes be attributed purely to 
formulation-related protein conformational effects, and to what extent are they influenced by 
other solution-related physicochemical and biochemical effects (such as chemical exchange 
and H-bonding)? In their study the authors used a 13C as well as 15N labelled version of 
filgrastim, so that a full resonance assignment could be achieved. Having this atomic level 
information in hand, they could discriminate between conformation-related and non-
conformation-related chemical shift changes. The effects of buffer composition were 
extensively investigated by titration studies, in which pH, ionic strength, and the 
concentration of excipients were changed gradually. It was concluded that the amide 1H-15N 
moieties can be too sensitive to pH effects, resulting in relatively large chemical shift 
differences in the 1H-15N HSQC spectra. Therefore, any observable spectral change of this 
kind is not necessarily the consequence of a conformational change of the protein backbone. 
It was suggested that in cases like the above-mentioned example, the far less “condition-
sensitive” but still very “conformation-sensitive” 1H-13C chemical shifts of the methyl signals 
observed in 1H-13C HSQC spectra should be compared (see also below) instead of a 
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comparison of the amide 1H and 15N resonances. In other cases, when the buffer conditions 
are the same for the compared samples and when no changes in the resonances are observed, 
it can be concluded with certainty that there are no differences in the protein conformation. 
Another important conclusion of this study was that while the CD method could not 
distinguish between single- or double-residue mutated protein variants, the 2D NMR 
fingerprint spectra of all of the investigated mutants were highly distinctive in that regard. 
Ghasriani and coworkers [19] performed an interlaboratory round robin test on 
filgrastim samples in which they showed that the deviations in the fingerprint spectra can be 
partly attributed to instrumental differences. 
A possible solution to avoid buffer-related spectral alterations is the use of less pH-
sensitive nuclei as reporters. Arbogast [17] introduced a special 1H-13C 2D correlation 
experiment which is less sensitive to the solution conditions than 1H-15N HSQC. In this 
experiment, the investigated moieties are the sidechain methyl groups of aliphatic amino 
acids such as isoleucine, leucine, alanine and valine residues which are in a distinct region of 
the spectra, and are usually well-separated from the signals of the excipients. The chemical 
shifts of the methyl groups are sensitive enough to local structural changes, but they are not 
involved in chemical exchange processes which make them less condition-sensitive reporters. 
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2.2  Approaches for comparative evaluation 
The goal of biosimilar development is to achieve the highest possible level of 
similarity between the reference and the biosimilar product. Using a complex and 
conscientiously planned analytical approach in order to determine the degree of 
(dis)similarity and to uncover the roots of the differences is of crucial importance. This 
requires not only the need to generate meaningful high-quality analytical data that can serve 
as a scientifically sound basis for the comparison, but also calls for the development of proper 
means by which the data-comparison itself is made. Comparing complex analytical data and 
assessing their degree of similarity, possibly by even somehow quantifying that similarity, is 
a challenging problem, especially when one is looking at this not simply as a formal 
chemometric problem, but as a task where biologically and structurally relevant differences 
in the analytical data should be separated from differences that are in those respects 
irrelevant. 
The simplest means of comparing NMR fingerprints is by human visual inspection.  
This form of evaluation can carry some subjective elements and yields a qualitative statement 
declaring the similarity or dissimilarity of the two structures. In spite of these two drawbacks, 
visual comparison has some distinct advantages: a) the expert eye can, under favorable 
conditions, interpret whether a given difference in the fingerprint pattern (Figure 4) is 
relevant regarding the compared protein structures; b) visual evaluation can easily encompass 
a large number of spectra; c) it is independent of the resolution of the spectra. Overall, the 
visual comparison of NMR fingerprints may still be still regarded as a reliable way of 
assessing structural similarity. [8,9].  
 
 
 
In contrast, chemometric tools give a quantitative measure of similarity and provide 
more objectivity, since the acceptance criteria can be defined prior to the analysis. The 
applicable mathematical approaches depend on the quality of the spectra. Less crowded, well-
resolved spectra allow a peak-to peak comparison of chemical shifts and signal intensities as 
applied, e.g., in the case of the 15N-1H HSQC spectrum of filgrastim. [23].  However, 
congested spectra often require the use of other forms of data sampling such as binning or 
bucketing [11]. The method of choice also depends on the number of spectra that should be 
compared. 
The number of compared spectra can also define the applied method of data 
evaluation. For pairwise comparisons, linear regression, sequential nearest-neighbor pattern 
recognition, or picture analysis can give a measure of similarity [11,12,24], while principal 
component analysis (PCA) [12] can be applied if a large of number of spectra is compared. 
 
2.3 Investigation of post-translational modifications 
Post-translational modifications (PTMs) are mostly enzymatically catalyzed covalent 
changes in the polypeptide chain, which occur after protein biosynthesis within the protein-
producing cell. These modifications include, for instance, the formation of disulfide bridges 
between cysteine residues, glycosylation, and deamidation. Sometimes subsequent chemical 
modifications, such as the PEGylation of a protein (i.e., the covalent attachment of 
polyethylene glycol polymer chains to the protein so as to increase its biological activity, 
efficacy and circulatory time, and to reduce its immunogenicity and antigenicity), are also 
called PTMs. PTMs play an essential role in the formation and maintenance of the protein 
tertiary structure, and thus in the efficacy and stability of the drug product. For example, the 
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glycosylation pattern is a key factor determining the immunogenic properties of the product. 
Because PTMs must be identified and characterized even when present as minor components 
in the drug substance, their investigation is typically a mass spectrometry task. However, in 
certain cases NMR can provide invaluable complementary information on a PTM’s structure, 
especially with regard to configurational or conformational problems that are not accessible 
by MS. Based on the recent literature (see below), NMR can play an important role in the 
determination of disulfide bond configurations, the characterization of PEGylation, and 
glycan pattern analysis.  
Disulfide bonds between cysteine sidechains play a fundamental role in the formation 
of the tertiary structure of proteins, therefore their determination is of utmost importance. 
Although NMR applications for disulfide bond characterization were published in the field of 
biomolecular NMR [27], for biopharmaceutical proteins these methods are not feasible for a 
number of reasons. First, distance measurements between the β 1H nuclei of the covalently 
connected cysteine pairs by NOESY methods can be extremely difficult even for isotope-
enriched and well-characterized proteins, because the relevant (conformation-dependent) 1H-
1H distance is usually quite large and spin diffusion involving the pertinent cystein CH2 
moieties can significantly dilute the measured inter-cystein NOEs. In principle, one known 
way to get round this problem is to substitute the non-NMR-active sulfur atoms with NMR-
active selenium atoms, which would allow the measurement of the direct inter-selenocystein 
Se-Se through-bond connectivities. However, besides this being a biotechnologically rather 
difficult task, it is, similarly to isotopic enrichment, not an acceptable procedure in the 
framework of the biopharmaceutical industry. Fortunately, because 1D and 2D NMR 
fingerprints inherently encode all information about the HOS, including the disulfide pattern, 
a high degree of NMR fingerprint-level similarity is a very strong indication that the disulfide 
linkages are identical in the compared proteins. 
For PEGylated proteins, the identification of the PEGylation site is a critical issue in 
biosimilar characterization [1]. This task is typically performed by LC-MS methods, with 
which enzymatic protein digests are investigated at the residue level. Although this approach 
is usually successfully applicable, NMR can also be useful as a complementary method. 
Wang and coworkers [28] demonstrated on PEGylated interferon alpha-2b that by the 
combination of 1D and 2D NMR measurements the PEGylation site can be identified 
unambiguously for enzymatically digested and HPLC-separated PEGylated peptide samples 
[28]. The key step of the analysis was based on the fact that the enzymatic digestion leaves 
the PEG chain unaffected, which can be later separated by molecular weight. 
According to the FDA guidance [1], in the case of glycoproteins such as mAbs the 
detailed characterization of the glycosylation pattern and the demonstration of its similarity to 
that of the reference is critical. This is a rather challenging task because, on the one hand, 
glycans themselves have very complex structures. On the other hand, mAbs exhibit much 
heterogeneity in terms of the attached glycans, and some glycans are often present in such 
minor quantities that they can only be investigated by MS. When the desired level of 
structural identification is the constitution of the individual sugar units, MS is therefore the 
method of choice. However, when one needs to distinguish between isobaric sugar units, 
and/or more detailed structural information is required, NMR comes into play. For example, 
NMR is one of the few tools capable of providing direct information about the anomeric 
configuration of glycosidic linkages between the sugar units. A nice example of this 
application was given in a study [29] in which LC-MS/MS and NMR methods were 
integrated for the characterization of N-glycans of cetuximab. This paper showed that 
although NMR is less sensitive than MS, the proper combination of these techniques allows 
the unambiguous identification of isobaric glycan structures even at a concentration range of 
approximately 15 pmol. The authors suggested the use of their method on a routine basis 
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when, as in the case of cetuximab, immunogenic α-1,3-Gal and the N-glycolylneuraminic 
acid epitopes cannot be distinguished from their isobaric forms by the commonly applied 
methods. 
 
3. Quality control of raw materials and impurities 
In the development and production of biologics, the role of NMR extends way beyond 
the structural characterization of the protein drug substance. In fact, as discussed below, 
NMR can be usefully employed to address a number of other analytical problems that are an 
inherent part of the whole biotechnology process, such as the characterization of raw 
materials and impurities, and the quantification of the drug substance in the drug product. As 
such, NMR can be envisaged as playing a certain role in some process analytical technologies 
(PAT). Below we give a few examples of such less well-known uses of NMR in 
biotechnology.  
 
3.1 Extractables and leachables, and other small-molecule process-related impurities  
Regulatory authorities emphasize the requirements for the purity of the biological 
drug substances and drug products and for the identification of their product- and process-
related impurities [30]. Process-related impurities can originate from the manufacturing 
process, cell substrates (host cell proteins or DNA), fermentation (medium components, 
antibiotics), or downstream processing. The most common sources of small-molecule 
impurities are technology-related and/or extractable and leachable (L&E) compounds 
originating from the accessories of fermentation and raw material storage. Some common 
small-molecule process-related impurities and L&E compounds are isopropyl alcohol, acetic 
acid, ethyl acetate, acetone, silicone polymers, glycerol, plasticizers and antioxidants like 
sterically hindered phenolic antioxidants, etc. These impurities should be characterized 
analytically to the extent possible, and where feasible, their biological activities should be 
evaluated. The identification of such impurities besides the protein drug substance can be a 
rather difficult problem, often requiring a complex analytical approach using a variety of 
chromatographic and spectroscopic techniques such as thin layer chromatography (TLC), 
HPLC, HPLC-MS, GC, etc. Within the analytical repertoire employed for that purpose, NMR 
can find a significant and unique place due to its potential to detect and identify small-
molecule contaminations in complex solutions without the physical separation of the 
components. For example, Skidmore et al. [16] introduced for that purpose an NMR-based 
approach which exploits the differences between the relaxational properties of large proteins 
and small molecules. Based on this difference, they used the so-called Carr-Purcell-
Meiboom-Gill (CPMG) pulse sequence to decrease the intensities of the product without 
removing the protein from the solution (Figure 5).  
3.2 Protein quantification 
The determination of the absolute concentration of a protein drug substance in a drug 
product can be an analytically problematic task. This is because in some cases the commonly 
applied methods (such as UV-absorbance and colorimetric measurements) give contradictory 
results for a variety of reasons, and so alternative techniques should be evoked. [31] Under 
properly chosen experimental conditions, in principle the area under any given signal of a 1D 
1H NMR spectrum is directly proportional to the number of 1H nuclei contributing to that 
signal. This seems to make the method uniquely reliable and convenient for the determination 
of absolute concentrations by using a suitable reference compound whose concentration is 
known. However, in practice the relation between the intensity of the NMR signals and the 
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protein concentration is not that straightforward, and therefore the data acquisition and 
evaluation of the spectra need great care. The use of an internal reference compound is 
generally not recommended for NMR-based protein quantification, because one cannot 
exclude the possibility that the protein will interact with the reference molecule, potentially 
distorting the results. If separate and assignable resonances of the protein are observable in 
the 1D 1H NMR spectrum, or at least the number of 1H nuclei belonging to a given signal or 
specific spectral region can be determined, an external reference material can be used for 
protein quantification by taking into account the conditions of the solution and the parameters 
of the NMR measurement. Wider and coworkers discussed in detail [32] the critical 
parameters that should be considered in that regard. After adjusting identically as many 
physicochemical and NMR measurement parameters as possible in the reference and the 
analyte samples, one must be careful to take into account the possibility that an excitation 
pulse applied for exactly the same length of time may affect the spins in the two samples to a 
slightly different degree, yielding slight unwanted differences in signal strength. The authors 
introduced a formula and an ideal workflow (called PULCON) involving pulse calibration 
and other experimental parameters (such as the temperature and additional correction factors) 
so as to compensate for this effect [33]. Later, the PULCON method was improved further 
with non-1H-nucleus filtering [34] in order to make the method applicable for heavily 
overlapping cases, but this development requires isotopic labelling, consequently it has less 
relevance in the biopharmaceutical industry.  
Because a protein’s hydration shell is an inherent constituent of its 3D structure, 
protein NMR studies are practically always conducted in aqueous solutions, whereby a large 
signal due to water appears in the 1H NMR spectra, often covering important spectral regions 
and interfering severely with data evaluation. To alleviate this problem, several special NMR 
techniques that are commonly referred to as “water suppression” should be applied. In order 
to better appreciate the necessity of using these methods, it is worth pointing out that the 
concentrations of the water and protein 1H nuclei in the sample are on the order of 100M and 
<1mM, respectively; note that this is a difference of more than 6 orders of magnitude! This 
means that, without suppression, the water signal can completely dominate the spectrum and 
conceal the protein resonances. The fact that the protein signals can be made visible, allowing 
the collection of atomic-level structural information, shows the technical ingenuity of these 
water-suppression techniques. However, water suppression methods can introduce various 
inherent undesired artifacts in the spectrum, whereby their application represents one of the 
main technical difficulties in these types of NMR experiment. Performing the measurements 
in pure deuterated buffer would seem to be a trivial option to solve this problem, but in 
everyday practice it is truly difficult to implement this option. Moreover, buffer exchange 
steps deprive NMR from one of its main advantages over other techniques, namely its 
potential to examine the intact sample as it is. Wider and his team [32] pointed out that those 
water suppression techniques which saturate the protein signals, such as “presaturation”, must 
be avoided, since they have a detrimental effect on protein signal intensities as well [32]. 
Instead, those NMR experiments should be preferred which incorporate the so-called 
WATERGATE (water suppression by gradient tailored excitation) [35] building block, and 
the signal loss during the water suppression module of the pulse sequence has to be 
determined and considered as a correction factor when the concentration is calculated by the 
given formula. In cases where well-resolved peaks are not present in the 1H spectrum, 
estimation of the number of protons 1H nuclei and integration within specific spectral regions 
can be performed. This approach however must be treated with reservations and should be 
applied only for the comparison of samples rather than for the measurement of absolute 
protein concentration.  
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In order to reliably carry out the 1H NMR integration and to be able to calculate the 
protein concentration from the integral value, one must find a signal (or a cluster of signals) 
that is a) purely of protein origin; b) sufficiently well-resolved from other resonances; c) for 
which we know exactly the number of contributing protein 1H nuclei. For large proteins such 
as therapeutic mAbs that have a natural isotopic abundance and are accompanied by small 
molecules (components of the formulation buffer), it is in practice often almost impossible to 
find such protein signals, which can render the task of quantification rather arduous. This 
problem can be overcome by using an appropriate quantitative heteronuclear 2D method in 
which, for example, the areas under the separate methyl cross-peaks are integrated. As it was 
demonstrated recently [36,37], this approach carries a number of potential experimental 
biases when the common 2D NMR measurement methods are applied, even for small 
molecules. The reliability and accuracy of 2D correlation spectroscopy for concentration 
measurement depends on multiple factors, including the relaxation properties of the 
investigated molecule, the coupling constants between the correlated nuclei, and even the 
finer details of the pulse sequence that generates the 2D spectrum. All this makes the 
approach quite problematic and requires the validation of the method for each individual 
case. Hopefully, validated and universally applicable quantitative 2D NMR methods will be 
developed in the near future. 
3.3 Analysis of cell culture medium composition 
During the development of the upstream processes in which biomolecules are 
manufactured through fermentation, having the analytical capability to monitor the 
composition of the spent culture medium can be of much value. [38,39] When multiple small-
molecule nutrients of the culture medium are being identified and quantified simultaneously, 
the procedure becomes methodically identical with the well-known field of metabonomics, 
which essentially deals with the quantitative analytical measurement of the dynamic 
metabolic profile of living systems and the statistical evaluation of the data. When  these 
techniques were applied to the analysis of the spent fermentation broth of mammalian cell 
cultures, the literature sometimes referred to these studies as “fermentanomics” [39–41]. 
Traditionally, metabonomic studies are performed by LC-MS, NMR or a combination of the 
two techniques, depending on the sample number, and the desired information. Nowadays, in 
an industrial environment high-throughput techniques are widely used instead of adjusting 
the parameters one by one from one fermentation procedure to another in order to facilitate 
the optimization of the parameters of protein production. While large-scale bioreactors are 
often equipped with online detectors to follow the concentration-changes of specific nutrients 
and metabolites, the current solutions for the online monitoring of small-volume high-
throughput-screening fermentation devices are limited in terms of the number of observable 
parameters. At this point, well-established NMR-based metabonomics tools come into play, 
since they have several advantages over LC-MS [42,43]. In particular, these NMR 
applications require minimal sample manipulation, they have high reproducibility and allow 
high-throughput data acquisition, and the accompanying statistical data analysis techniques 
are well consolidated. 
In a significant study, Bradley et al. applied NMR fermentanomics for the 
optimization of the feed medium of mammalian cell cultures. [39]. In that work the authors 
used a series of so-called first-increment 1D 1H-NOESY experiments with water suppression 
(these are essentially 1D 1H NMR spectra by appearance that are more suitable for 
quantification than a conventional 1D 1H NMR spectrum) for the time-course nutrient-
concentration profiling of fermentations. After a 4-fold dilution of the centrifuged medium 
supernatant by D2O-based phosphate buffer, a 20 minute per sample total experimental time 
was achieved, enabling high-throughput data recording and resulting in an appropriate signal-
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to-noise ratio, proper pH control, and excellent water suppression. The nutrient resonances 
were assigned by the concerted use of public chemical shift databases and spiking with 
known purchased compounds, and data evaluation was aided by software designed for the 
spectral analysis of liquid mixtures. The authors demonstrated that the time-consuming and 
labor-intensive process of culture medium optimization can be very effectively facilitated by 
the fermentanomics approach: a correlation was observed between the depletion of certain 
NMR-observable nutrients and mAb productivity, and in that particular case histidine was 
identified as one of the productivity-limiting nutrients. This study also gave a surprising 
result: it revealed the accumulation of such volatile acetate and formate metabolites in the 
samples which had not been previously reported in mammalian cell cultures when 
investigated by LC-MS, confirming that NMR is the primary method for fermentanomics. 
The authors suggested a protocol for the monitoring of intracellular metabolites as well by 
using a combination of cell lysis and washing steps, followed by NMR measurements. In the 
case of these protein-rich samples CPMG-based NMR methods were preferred to filter out 
the broad lines of macromolecules.  
In a later study [40] a similar NMR approach was used, and further culture medium 
optimization was achieved, in the case of an immunoglobulin G (IgG) antibody producing 
cell culture, preventing the depletion of several nutrients from the fermentation which 
resulted in a higher yield of the desired antibody without any undesirable impact on the 
protein structure and N-linked glycan profile. A further improvement on the fermentanomic 
approach was subsequently published [41] in which multivariate data analysis (MVDA) was 
introduced for the statistical evaluation of the NMR spectra of the spent culture media. By 
this alternative approach product quality attributes (such as protein glycosylation) could be 
correlated with process variables. It was demonstrated that fermentanomics, together with 
MVDA, is efficiently applicable not only for the rapid finding of the optimal composition of 
the culture media, but also for process optimization and for controlling the consistency of 
batch-to-batch variations of the product quality attribute profile. 
The need for the compositional analysis of the raw materials used in mammalian cell 
fermentations also crops up from the point of view of the internal quality control of the 
purchased culture media and feeds. Such quality control is essential to ensure the sustainable 
batch-to-batch quality of the produced protein drug substances. The characterization of these 
complex mixtures, which contain essential nutrients and vitamins in a well-defined ratio, is 
challenging because vendors usually regard their compositions as proprietary knowledge. 1D 
1H NMR spectra provide, as described above, fingerprint-like quantitative and qualitative 
information (see Fig. 6) on almost all of the organic components and can demonstrate the 
batch-to-batch identity of the purchased media in a robust, quick and convenient way, 
requiring much simpler sample preparation than with other methods such as HPLC-MS.   
 
 
4. Conclusions 
Based partly on our own experiences and partly on the recent literature, in this review 
we collected the main areas in which modern NMR spectroscopy can usefully contribute to 
the development and the quality control of biotechnological drug substances in a 
pharmaceutical industrial environment, mainly focusing in that regard on protein biosimilars.  
We discussed the unique capability of NMR to provide highly detailed fingerprint-like 
information about a protein’s primary and high-order structure at an atomic resolution. 
Several 1D and 2D NMR experiments can be used to generate various types of such 
fingerprints, and these offer powerful tools for comparing the structural similarity of the 
follow-on and the reference proteins. In addition, we attempted to draw attention to the utility 
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of NMR in related analytical tasks such as the identification of post-translational 
modifications and small-molecule impurities, the quantification of the protein drug substance 
in the drug product, and the analysis of cell culture media. The presented methods 
demonstrate the great benefits that NMR can provide, as well as the limitations inherent to 
this technique. Most of the papers that we found to be relevant to this topic had been 
published in the last three to five years, indicating that this field is young and is rapidly 
evolving. With the expected future advancements in the sensitivity and resolution of NMR, 
its role should be further expanding conspicuously in the field of biopharmaceuticals. This 
optimistic future prospect however will not only depend on the increasing technical 
capabilities of NMR, but also on whether the general appreciation of what NMR can do in the 
biopharmaceutical industry will also increase in the minds of the non-NMR experts. 
Biotechnology R&D programs are multidisciplinary projects whose success depends on the 
close collaboration of its expert participants and a mutual understanding of the scopes and 
limitations of each analytical technique being used. Thus, such general understanding of the 
role of NMR, at least at a conceptual level, is critical, and we modestly hope that this review 
may have contributed to that goal.   
 
16 
 
References 
[1] CDER/CBER, FDA, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product 
Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, 
Guid. Ind. (2015). 
[2] D.S. Wishart, Characterization of biopharmaceuticals by NMR spectroscopy, TrAC - Trends Anal. Chem. 
48 (2013) 96–111. doi:10.1016/j.trac.2013.03.009. 
[3] European Medicines Agency, Guideline on Similar Biological Medicinal Products Containing 
Biotechnology-Derived Proteins As Active Substance: Quality Issues, London, 2006. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC50000395
3.pdf. 
[4] S. Berkowitz, J. Engen, J. Mazzeo, G. Jones, Analytical tools for characterizing biopharmaceuticals and 
the implications for biosimilars, Nat. Rev. Drug Discov. 11 (2013) 527–540. 
doi:10.1038/nrd3746.Analytical. 
[5] H. Wei, J. Mo, L. Tao, R.J. Russell, A.A. Tymiak, G. Chen, R.E. Iacob, J.R. Engen, Hydrogen/deuterium 
exchange mass spectrometry for probing higher order structure of protein therapeutics: Methodology 
and applications, Drug Discov. Today. 19 (2014) 95–102. doi:10.1016/j.drudis.2013.07.019. 
[6] J. Fang, Y.Q. Yu, A. Beck, W. Chen, A. Chakraborty, HDX-MS for Assessing Comparability Between 
Innovator and Biosimilar Biotherapeutics, Poster. (2016) 2016. 
[7] J. Pan, S. Zhang, C.H. Borchers, Comparative higher-order structure analysis of antibody biosimilars using 
combined bottom-up and top-down hydrogen-deuterium exchange mass spectrometry, Biochim. 
Biophys. Acta - Proteins Proteomics. 1864 (2016) 1801–1808. doi:10.1016/j.bbapap.2016.08.013. 
[8] F. Sorgel, A. Schwebig, J. Holzmann, S. Prasch, P. Singh, M. Kinzig, Comparability of biosimilar filgrastim 
with originator filgrastim: Protein characterization, pharmacodynamics, and pharmacokinetics, 
BioDrugs. 29 (2015) 123–131. doi:10.1007/s40259-015-0124-7. 
[9] J. Visser, I. Feuerstein, T. Stangler, T. Schmiederer, C. Fritsch, M. Schiestl, Physicochemical and functional 
comparability between the proposed biosimilar rituximab GP2013 and originator rituximab, BioDrugs. 
27 (2013) 495–507. doi:10.1007/s40259-013-0036-3. 
[10] D.I. Freedberg, Using nuclear magnetic resonance spectroscopy to characterize biologicals., Dev. Biol. 
17 
 
(Basel). 122 (2005) 77–83. 
[11] C.A. Amezcua, C.M. Szabo, Assessment of Higher Order Structure Comparability in Therapeutic Proteins 
Using Nuclear Magnetic Resonance Spectroscopy, J Pharm Sci. 102 (2013) 1724–1733. 
doi:10.1002/jps.23531. 
[12] B. Japelj, G. Ilc, J. Marušič, J. Senčar, D. Kuzman, J. Plavec, Biosimilar structural comparability assessment 
by NMR: from small proteins to monoclonal antibodies, Sci. Rep. 6 (2016) 32201. 
doi:10.1038/srep32201. 
[13] L. Poppe, J.B. Jordan, K. Lawson, M. Jerums, I. Apostol, P.D. Schnier, Profiling formulated monoclonal 
antibodies by 1H NMR spectroscopy, Anal. Chem. 85 (2013) 9623–9629. doi:10.1021/ac401867f. 
[14] X.U.M. Fang, J.D.F. Yan, Higher Order Structure Assessment of Biosimilars Based on the Correlation of 
NMR Spectral Fingerprints, Chinese J. Magn. Reson. 32 (2015) 342–353. doi:10.11938/cjmr20150216. 
[15] J. Franks, J.N. Glushka, M.T. Jones, D.H. Live, Q. Zou, J.H. Prestegard, Spin Diffusion Editing for Structural 
Fingerprints of Therapeutic Antibodies, Anal. Chem. 88 (2016) 1320–1327. 
doi:10.1021/acs.analchem.5b03777. 
[16] K. Skidmore, D. Hewitt, Y.H. Kao, Quantitation and characterization of process impurities and 
extractables in protein-containing solutions using proton NMR as a general tool, Biotechnol. Prog. 28 
(2012) 1526–1533. doi:10.1002/btpr.1620. 
[17] L.W. Arbogast, R.G. Brinson, J.P. Marino, Mapping Monoclonal Antibody Structure by 2D 13C NMR at 
Natural Abundance, Anal. Chem. 87 (2015) 3556–3561. doi:10.1021/ac504804m. 
[18] M.R. Palmer, B.R. Wenrich, P. Stahlfeld, D. Rovnyak, Performance tuning non-uniform sampling for 
sensitivity enhancement of signal-limited biological NMR, in: J. Biomol. NMR, 2014: pp. 303–314. 
doi:10.1007/s10858-014-9823-5. 
[19] H. Ghasriani, D.J. Hodgson, R.G. Brinson, I. McEwen, L.F. Buhse, S. Kozlowski, J.P. Marino, Y. Aubin, D.A. 
Keire, Precision and robustness of 2D-NMR for structure assessment of filgrastim biosimilars, Nat. 
Biotechnol. 34 (2016) 139–141. doi:10.1038/nbt.3474. 
[20] D.J. Hodgson, Y. Aubin, Assessment of the structure of pegylated-recombinant protein therapeutics by 
the NMR fingerprint assay, J. Pharm. Biomed. Anal. 138 (2017) 351–356. 
doi:10.1016/j.jpba.2017.01.058. 
18 
 
[21] X. Jin, S. Kang, H. Kwon, S. Park, Heteronuclear NMR as a 4-in-1 analytical platform for detecting 
modification-specific signatures of therapeutic insulin formulations, Anal. Chem. 86 (2014) 2050–2056. 
doi:10.1021/ac403218f. 
[22] N. Panjwani, D.J. Hodgson, S. Sauvé, Y. Aubin, Assessment of the effects of pH, formulation and 
deformulation on the conformation of interferon alpha-2 by NMR, J. Pharm. Sci. 99 (2010) 3334–3342. 
doi:10.1002/jps.22105. 
[23] Y. Aubin, D.J. Hodgson, W.B. Thach, G. Gingras, S. Sauvé, Monitoring Effects of Excipients, Formulation 
Parameters and Mutations on the High Order Structure of Filgrastim by NMR, Pharm. Res. 32 (2015) 
3365–3375. doi:10.1007/s11095-015-1713-3. 
[24] S.̌ Župerl, P. Pristovšek, V. Menart, V. Gaberc-Porekar, M. Novič, Chemometric approach in 
quantification of structural identity/similarity of proteins in biopharmaceuticals, J. Chem. Inf. Model. 47 
(2007) 737–743. doi:10.1021/ci6005273. 
[25] K. Chen, D.S. Long, S.C. Lute, M.J. Levy, K.A. Brorson, D.A. Keire, Simple NMR methods for evaluating 
higher order structures of monoclonal antibody therapeutics with quinary structure, J. Pharm. Biomed. 
Anal. 128 (2016) 398–407. doi:10.1016/j.jpba.2016.06.007. 
[26] L.W. Arbogast, R.G. Brinson, T. Formolo, J.T. Hoopes, J.P. Marino, 2D 1HN, 15N Correlated NMR 
Methods at Natural Abundance for Obtaining Structural Maps and Statistical Comparability of 
Monoclonal Antibodies, Pharm. Res. 33 (2016) 462–475. doi:10.1007/s11095-015-1802-3. 
[27] M. Mobli, G.F. King, NMR methods for determining disulfide-bond connectivities, Toxicon. 56 (2010) 
849–854. doi:10.1016/j.toxicon.2010.06.018. 
[28] Y.S. Wang, S. Youngster, J. Bausch, R. Zhang, C. McNemar, D.F. Wyss, Identification of the major 
positional isomer of pegylated interferon alpha-2b., Biochemistry. 39 (2000) 10634–10640. 
[29] A. Wiegandt, B. Meyer, Unambiguous Characterization of N Glycans of Monoclonal Antibody Cetuximab 
by Integration of LC-MS/MS and 1H-NMR Spectroscopy, Anal. Chem. 86 (2014) 4807−4814. 
doi:dx.doi.org/10.1021/ac404043g. 
[30] C. ICH, Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological 
Products, Eur. Med. Agency. (1999) 1–17. papers2://publication/uuid/3FAC0933-7C71-4C87-BC90-
81C0D1DE0716. 
19 
 
[31] A.C. Conibear, N.L. Daly, D.J. Craik, Quantification of small cyclic disulfide-rich peptides., Biopolymers. 98 
(2012) 518–24. doi:10.1002/bip.22121. 
[32] G. Wider, L. Dreier, Measuring protein concentrations by NMR spectroscopy, J. Am. Chem. Soc. 128 
(2006) 2571–2576. doi:10.1021/ja055336t. 
[33] D.I. Hoult, R.E. Richards, The signal-to-noise ratio of the nuclear magnetic resonance experiment, J. 
Magn. Reson. 24 (1976) 71–85. doi:10.1016/0022-2364(76)90233-X. 
[34] L. Dreier, G. Wider, Concentration measurements by PULCON using X-filtered or 2D NMR spectra, Magn. 
Reson. Chem. 44 (2006). doi:10.1002/mrc.1838. 
[35] M. Piotto, V. Saudek, V. Sklenar, Gradient-Tailored Excitation for Single-Quantum Nmr-Spectroscopy of 
Aqueous-Solutions, J. Biomol. Nmr. 2 (1992) 661–665. 
[36] F. Fardus-Reid, J. Warren, A. Le Gresley, Validating heteronuclear 2D quantitative NMR, Anal. Methods. 
8 (2016) 2013–2019. doi:10.1039/C6AY00111D. 
[37] P. Giraudeau, Quantitative 2D liquid-state NMR, Magn. Reson. Chem. 52 (2014) 259–272. 
doi:10.1002/mrc.4068. 
[38] P. Gronemeyer, R. Ditz, J. Strube, Trends in Upstream and Downstream Process Development for 
Antibody Manufacturing, (2014) 188–212. doi:10.3390/bioengineering1040188. 
[39] S.A. Bradley, A. Ouyang, J. Purdie, T.A. Smitka, T. Wang, A. Kaerner, Fermentanomics: Monitoring 
mammalian cell cultures with NMR spectroscopy, J. Am. Chem. Soc. 132 (2010) 9531–9533. 
doi:10.1021/ja101962c. 
[40] E.K. Read, S.A. Bradley, T.A. Smitka, C.D. Agarabi, S.C. Lute, K.A. Brorson, Fermentanomics informed 
amino acid supplementation of an antibody producing mammalian cell culture, Biotechnol. Prog. 29 
(2013) 745–753. doi:10.1002/btpr.1728. 
[41] A.S. Rathore, S. Kumar Singh, M. Pathak, E.K. Read, K.A. Brorson, C.D. Agarabi, M. Khan, 
Fermentanomics: Relating quality attributes of a monoclonal antibody to cell culture process variables 
and raw materials using multivariate data analysis, Biotechnol. Prog. 31 (2015) 1586–1599. 
doi:10.1002/btpr.2155. 
[42] M.R. Viant, E.S. Rosenblum, R.S. Tieerdema, NMR-based metabolomics: a powerful approach for 
20 
 
characterizing the effects of environmental stressors on organism health., Environ. Sci. Technol. 37 
(2003) 4982–9. http://www.ncbi.nlm.nih.gov/pubmed/14620827. 
[43] Abdul-Hamid M. Emwas, The Strengths and Weaknesses of NMR Spectroscopy and Mass Spectrometry 
with Particular Focus on Metabolomics Research, in: J.B. Bjerrum (Ed.), Metabonomics Methods Protoc., 
2015: pp. 161–193. doi:10.1007/978-1-4939-2377-9_13. 
 
21 
 
 
Figure 1 1D 1H NMR spectrum of a middle-sized therapeutic protein (17kDa) (upper trace) and that 
of a 150 kDa monoclonal antibody drug product, which contains approximately seven times more 1H 
nuclei (lower trace). Because of the increased spectral congestion and the line-broadening effects 
associated with the increased molecular weight, in the latter case far fewer resolved signals can be 
detected in the spectrum. The intensive signals in the aliphatic region correspond to the excipients. 
 
 
 
 
 
 
Figure 2 Average molecular weight of some randomly selected approved therapeutic proteins in the 
US and EU. The average molecular weight influences the appropriate NMR approach to investigate 
the structural properties.  
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Figure 3 Part of a 1H-15N HSQC spectrum recorded in-house at natural isotopic abundance from of a 
~  20kDa protein at 800MHz 1H frequency. 
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Figure 4 Overlaid view of two 1H-15N HSQC spectra of a small protein (~ 6 kDa). 
Clearly, the spectra are very similar but not completely identical. While the number of peaks 
and the majority of peak positions match, slight chemical shift differences can be observed in 
the case of some signal pairs because of a slight difference in the pH of the two samples. 
Being aware of this difference in the solution conditions, a human expert can make the 
judgment that the two corresponding protein structures are similar, while a chemometric 
approach would indicate dissimilarity in this specific case. 
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Figure 5. In NMR spectroscopy, the signals coming from the protein and small-molecule impurities 
can be distinguished without the physical separation of the components. The lower trace shows the 
normal 1D 1H NMR spectrum (800MHz, in-house measurement) of a biological drug product. By the 
application of a CPMG-based signal-suppression scheme, the signals of the protein can be eliminated 
from the spectrum (upper trace). The doublet at 1.17 ppm corresponds to a small-molecule impurity, 
while the intensive signal at 2 ppm comes from a buffer component. 
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Figure 6. 1H NMR spectra (800MHz, in-house measurement obtained with water suppression) of 
different mammalian cell culture media. From a series of this simple experiment, useful qualitative 
and quantitative information can be collected from the mixture, which facilitates medium 
development and can potentially serve as an in-process quality control tool. 
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Table 1. Investigated biological products referenced in the literature, and the applied NMR 
approaches. 
INVESTIGATED PROTEIN AVERAGE 
MOLECULAR 
WEIGHT 
APPLIED NMR TECHNIQUES REFERENCE 
Cubicin (Daphtomycin) 1.6 kDa 15N HSQC [14] 
Insulin 7.6 kDa 15N HSQC [21] 
Interferon-α2 19.2 kDa 15N HSQC [22] 
MET-G-CSF 18.8 Da 1H 
2D NOESY 
15N HSQC 
[8] 
[24] 
[19] 
PEG Interferon-α2B >19.2 kDa 15N HSQC [20] 
PEG-GCSF ~ 38.8 kDa 15N HSQC [20] 
Rituximab 143.9 Da 1D-1H 
1D-1H NOESY 
[9] 
[25] 
Infliximab 144.2 kDa 1D-1H [25] 
Trastuzumab 145.5 kDa 1D-1H [14] 
mAb (unidentified) ~ 150 kDa 1D-1H enhanced by pulsed 
field gradient stimulated echo 
[13] 
mAb (unidentified) ~ 150 kDa enzymatic digestion, 
1H, 15N SOFAST-HMQC 
[26] 
mAb (unidentified) ~ 150 kDa enzymatic digestion, 
1H, 15N SOFAST-HMQC 
[26] 
 
 
 
